Kristin Peck is Chief Executive Officer of Zoetis, the world’s leading animal health company and a member of the Fortune 500. Ms. Peck is also a member of the Zoetis Board of Directors.
Prior to becoming CEO in 2020, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at Zoetis. Ms. Peck helped usher Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in many roles at the company, including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Named by Barron’s as one of the top CEOs in 2022, and by Fortune as a 2020 Businessperson of the Year, Ms. Peck has been recognized for her leadership and Zoetis' strong performance in challenging times.
Before joining Zoetis, Ms. Peck served as executive vice president, Worldwide Business Development and Innovation at Pfizer Inc., and as a member of Pfizer's Executive Leadership Team. In that role, she was responsible for the evaluation of strategic alternatives for Pfizer's Animal Health and Nutrition businesses – paving the way for a public animal health company and attractive investment opportunity.
Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.
Ms. Peck serves on the boards of BlackRock, Mayo Clinic, and Columbia Business School, and is a member of the Business Roundtable. She is also a Board member of Catalyst, a global non-profit that helps companies accelerate women into leadership. In addition, she is president of HealthforAnimals, the global animal health association, which advocates for the fundamental role of healthy animals in improving global wellbeing, sustainability and prosperity.
Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School.